Share Twitter LinkedIn Facebook Email Michelle Dawson Franchise Head Hematology, US Medical Affairs at AstraZeneca Discusses Acalabrutinib Monotherapy In CLL At The 60th ASH Annual Meeting on Dec 1, 2018.
Positive Outcomes & Tolerability Sonrotoclax + Zanubrutinib in TN-CLL/SLL – ASH 2023 Updates Chronic Lymphocytic Leukemia 1 Min Read
BTK Inhibitor Use and Social Determinants in CLL / SLL [ASH 2023] Chronic Lymphocytic Leukemia 2 Mins Read
Elevate-TN: Treatment-Naive CLL Treated with Acalabrutinib – ASH Chronic Lymphocytic Leukemia 2 Mins Read